ODAC Will Have Bigger Role At Avastin Hearing Than Previously Described

FDA tells the Oncologic Drugs Advisory Committee it will have a voting role at the two-day hearing, in contrast with CDER's original expectation that the panel would provide advice and recommendations but not vote.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet